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Nasopharyngeal cancer (NPC) mortality shows great disparity between endemic high risk areas, where non-keratinizing
carcinoma (NKC) histology is prevalent, and non-endemic low risk regions, where the keratinizing squamous cell carcinoma
(KSCC) type is more frequent. We used the World Health Organization database to calculate NPC mortality trends from 1970
to 2014 in several countries worldwide. For the European Union (EU), the United States (US) and Japan, we also predicted
trends to 2020. In 2012, the highest age-standardized (world standard) rates were in Hong Kong (4.51/100,000 men and
1.15/100,000 women), followed by selected Eastern European countries. The lowest rates were in Northern Europe and Latin
America. EU rates were 0.27/100,000 men and 0.09/100,000 women, US rates were 0.20/100,000 men and 0.08/100,000
women and Japanese rates were 0.16/100,000 men and 0.04/100,000 women. NPC mortality trends were favourable for sev-
eral countries. The decline was 215% in men and 25% in women between 2002 and 2012 in the EU, 212% in men and
29% in women in the US and about 230% in both sexes in Hong Kong and Japan. The favourable patterns in Europe and the
United States are predicted to continue. Changes in salted fish and preserved food consumption account for the fall in NKC.
Smoking and alcohol prevalence disparities between sexes and geographic areas may explain the different rates and trends
observed for KSCC and partially for NKC. Dietary patterns, as well as improvement in management of the disease, may partly
account for the observed trends, too.
There were about 85,000 incident cases and over 50,000
deaths from nasopharyngeal carcinoma (NPC) worldwide in
2012.1 The global distribution of incidence and mortality
showed a unique disparity, with extremely high rates (over
20–30/100,000 men and 10/100,000 women) in some regions
of Southern China,2–6 Hong Kong,7–9 Taiwan,10 Singapore,9
other areas of Southeast Asia,11–13 selected Chinese migrants
(mostly to North America),9,14–17 and in North Africa.18,19 In
non-endemic areas including most western countries, Latin
America and Japan, NPC is a rare malignancy with incidence
rates lower than 1/100,000.20,21
In high risk areas, the most frequent histotype is non-
keratinizing carcinoma (NKC, differentiated and undifferenti-
ated), while keratinizing squamous cell carcinoma (KSCC) is
frequent in low risk areas, although NKC is present as well.22
A recognized risk factor for NKC is Epstein-Barr virus
(EBV) infection, although cofactors are implied.23 Among
these, there are salted ﬁsh and preserved food consump-
tion.24–26 Tobacco and alcohol are involved in both NKC and
KSCC.27 Some aspects of diet,28,29 and occupational exposure
to wood dust in the past have been associated with KSCC.
Genetic predisposition also plays a role in both histotypes.30,31
Over the last decade, lifestyle and dietary habits have
changed worldwide, particularly in high NKC risk populations,
and NPC management and treatment has improved.6,32,33
Therefore, we conducted a comprehensive up to date analysis
of global trends in NPC mortality.
Material and Methods
We used the World Health Organization (WHO) database,
available on electronic support, to obtain data on ofﬁcial
death certiﬁcation for NPC.34 We derived ﬁgures for a total
of 42 countries and the EU as a whole from 1970 to 2014 or
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the most recent available year. Due to accuracy, completeness
and availability issues, for Spain we only considered data
since 1984, for Mexico since 1998 and for the Republic of
Korea since 1995.35 We included countries which met either
of the following two criteria: 5 million or more inhabitants,
at least 50 deaths recorded in 2005–2009, and provided data
for the 2000s. We considered the European Union (EU) as a
whole (28 countries as of July 2013, minus Cyprus due to
data unavailability), 25 separate European countries (EU and
non-EU), 10 countries from the Americas, and 7 other coun-
tries or economic areas worldwide.
We did not perform extrapolation for missing data, except
for the calculation of the EU rates where, when data were
not available for one or more years for a country, we used
the nearest available data.
During the calendar period considered, three Revisions of
the International Classiﬁcation of Diseases (ICD) were
used.36–38 NPC deaths were recoded for all countries accord-
ing to the 10th Revision of the ICD (ICD 10 code C11).
We used resident population estimates, based on ofﬁcial
censuses, from the WHO database. When population data
were missing, we obtained them from EUROSTAT and the
Pan American Health Organization (PAHO) databases.39,40
PAHO provided data stratiﬁed by sex and 5-year age groups
(from 0 to 4, to 801 years) for selected years only (1995,
2000 and 2005) and stratiﬁed by sex and broader age groups
(<1, 1–4, 5–14, 15–44, 45–64 and 651 years) for the remain-
ing years. We, therefore, obtained estimates for the 5-year
age groups interpolating data from 1995, 2000 and 2005.
Using certiﬁed deaths and resident population, we calcu-
lated age-speciﬁc NPC death rates for each 5-year age group
(from 0–4 to 851 years and from 0–4 to 801 for the Ameri-
cas) and calendar year or quinquiennium. We then computed
age-standardized mortality rates per 100,000 people, based on
the world standard population.41
To identify signiﬁcant changes in mortality trends, we
used joinpoint regression models, allowing for a maximum of
three jointpoints.42 For major countries worldwide (including
the EU as a whole) we calculated estimated annual percent
changes (APC) and the average annual percent change
(AAPC) over the entire considered period.43,44
For the EU as a whole, the United States and Japan, we
predicted NPC number of deaths and rates for the year 2020.
We ﬁtted joinpoint regression models, allowing for up to ﬁve
joinpoints. In this case, we considered the number of certiﬁed
deaths in each 5-year age group, with the aim to identify the
most recent trend slope. Subsequently, we applied a linear
regression to various age groups over the period identiﬁed by
the joinpoint model to calculate the predicted age-speciﬁc
certiﬁed number of deaths, and the corresponding 95% pre-
diction intervals. Using the predicted population data from
EUROSTAT, the United States Census Bureau, and from the
Japanese National Institute of Population and Social Security
Research databases we computed predicted age-standardized
mortality rates.39,45,46
Results
Table 1 gives, for all the countries considered and the EU as
a whole, mortality rates and number of deaths from NPC, for
men and women, at all ages around 2002 (2000–2004 quin-
quiennium), 2007 (2005–2009 quinquiennium) and 2012
(single year; when missing we considered the closest available
year—i.e., 2011 for the EU, France, Canada, Australia and
New Zealand), and numbers of deaths for the year 2012 (or
closest available). Table 1 also gives the percent change
between 2012 and 2002.
Between 2002 and 2012, NPC mortality rates decreased
from 0.32 to 0.27/100,000 men (214.7%) in EU. Most major
European countries showed favourable trends, except Belgium,
Germany, Greece and Portugal.
The decline was 211.7% in the United States (0.20/
100,000 men in 2012). Across major Latin American coun-
tries, Colombia, Cuba and Mexico showed downward trends.
Mexico had one of the lowest NPC mortality rates in 2012,
0.07/100,000 men. Argentina, Brazil, Chile and Venezuela
showed upward trends.
Mortality rates in Hong Kong were the highest among the
available areas, 4.5/100,000 in 2012. However, Hong Kong
and Japan (that had much lower rates, 0.16/100,000) showed
substantial declines, with percent changes of 230.0%. Other
Eastern and Paciﬁc countries considered showed favourable
trends.
NPC mortality rates in women were systematically lower
than in men. Change in the EU was 25.4%, and the rate was
0.09/100,000 women. France and Italy showed the greatest
falls among major European countries. Female NPC mortality
trends were also downwards in most smaller countries.
In the United States, the fall was 29.2%, from 0.09/
100,000 to 0.08/100,000 between 2002 and 2012. Colombia
also had a similar fall, and Cuba showed a decline from
What’s new?
Nasopharyngeal cancer (NPC) shows major variations between high and low-risk areas. Over the last decade, lifestyle and die-
tary habits have changed worldwide, particularly in high-risk populations, and NPC management and treatment has improved.
Here, the authors used the World Health Organization database to calculate NPC mortality trends from 1970 to 2014 in sever-
al countries worldwide. Declines in mortality were observed in most areas of the world for the major histological types, follow-
ing patterns that are predicted to continue in the near future. Decreased salted fish and preserved food consumption and
tobacco smoking may partly or largely explain these trends.
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Table 1. Age-standardized (world population) mortality rates per 100,000 men and women from nasopharyngeal cancer at all ages in select-
ed countries around 2002 (2000–2004 quinquennium), 2007 (2005–2009 quinquennium) and in 2012 (or closest available), corresponding
percent change (2012 vs. 2002) and number of deaths for 2012
Men Women
Death rate/100,000
% change
(2012/2002)
Number of
deaths 2012
Death rate/100,000
% change
(2012/2002)
Number of
deaths 20122002 2007 2012 2002 2007 2012
EU (2011) 0.32 0.28 0.27 214.7 1103 0.09 0.09 0.09 25.4 441
Austria 0.24 0.24 0.25 3.3 18 0.10 0.06 0.03 264.2 3
Belgium 0.18 0.13 0.18 0.6 15 0.04 0.04 0.05 33.3 5
Bulgaria 0.21 0.40 0.34 59.4 19 0.06 0.09 0.12 95.2 10
Croatia 0.36 0.33 0.52 44.8 22 0.14 0.09 0.04 274.3 4
Czech Republic 0.32 0.27 0.27 216.9 23 0.07 0.08 0.04 243.7 6
Denmark 0.17 0.15 0.10 243.9 5 0.09 0.10 0.03 262.5 2
France (2011) 0.25 0.20 0.21 216.9 104 0.06 0.06 0.04 235.5 28
Germany 0.15 0.14 0.16 1.9 117 0.05 0.06 0.05 3.9 44
Greece 0.51 0.50 0.56 10.6 52 0.16 0.12 0.17 5.7 17
Hungary 0.59 0.48 0.51 213.0 36 0.12 0.14 0.07 241.9 11
Italy 0.39 0.28 0.31 220.9 168 0.10 0.09 0.06 242.2 38
Netherlands 0.18 0.15 0.16 29.5 22 0.07 0.08 0.07 0.0 8
Poland 0.39 0.39 0.31 219.4 89 0.15 0.12 0.13 211.6 42
Portugal 0.52 0.50 0.66 27.3 55 0.14 0.14 0.16 15.6 15
Romania 0.95 0.81 0.93 21.5 138 0.26 0.24 0.26 20.8 44
Slovakia 0.56 0.44 0.49 213.0 18 0.07 0.09 0.10 38.6 5
Spain 0.53 0.44 0.36 232.5 143 0.12 0.11 0.10 214.2 55
Sweden 0.16 0.17 0.10 238.5 8 0.04 0.06 0.03 217.1 3
UK 0.19 0.17 0.15 224.2 82 0.07 0.06 0.08 9.7 39
Israel 0.43 0.27 0.12 273.0 5 0.13 0.08 0.04 272.9 2
Kyrgyzstan 0.40 0.47 0.53 32.6 12 0.15 0.21 0.12 221.8 2
Norway 0.12 0.12 0.12 24.0 4 0.07 0.02 0.02 267.6 1
Republic of Moldova 1.19 1.05 1.00 216.3 22 0.41 0.39 0.29 230.7 8
Serbia 0.30 0.36 0.47 56.6 28 0.08 0.13 0.15 82.7 13
Switzerland 0.16 0.14 0.09 247.2 7 0.06 0.04 0.05 210.2 4
Canada (2011) 0.31 0.28 0.23 226.9 62 0.11 0.11 0.10 24.6 28
United States 0.22 0.21 0.20 211.7 454 0.09 0.08 0.08 29.2 212
Argentina 0.16 0.16 0.17 6.8 40 0.04 0.05 0.06 68.6 17
Brazil 0.20 0.21 0.21 5.0 219 0.07 0.07 0.08 12.5 92
Chile 0.06 0.07 0.09 44.1 8 0.02 0.02 0.03 35.0 3
Colombia 0.17 0.16 0.16 24.2 36 0.07 0.07 0.06 29.2 15
Costa Rica 0.63 0.48 0.35 244.7 9 0.20 0.15 0.17 213.1 4
Cuba 0.47 0.49 0.47 21.1 42 0.14 0.15 0.09 232.1 10
Guatemala 0.02 0.05 0.12 495.0 6 0.02 0.05 0.01 239.1 1
Mexico 0.07 0.08 0.07 28.3 33 0.04 0.03 0.05 19.5 29
Uruguay 0.36 0.45 0.21 240.9 4 0.12 0.17 0.06 247.1 2
Venezuela 0.17 0.18 0.26 47.7 34 0.08 0.08 0.06 231.3 10
Hong Kong 6.57 5.47 4.51 231.3 255 1.77 1.54 1.15 235.1 74
Japan 0.23 0.20 0.16 230.0 230 0.06 0.05 0.04 231.0 74
Republic of Korea 0.42 0.41 0.36 212.5 127 0.10 0.12 0.07 232.0 29
Australia (2011) 0.27 0.25 0.24 28.3 41 0.10 0.09 0.07 232.7 14
New Zealand (2011) 0.33 0.31 0.51 52.1 16 0.13 0.14 0.08 242.0 3
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0.14 in 2002 to 0.09/100,000 in 2012 (232.1%). In Hong
Kong, the fall was 235% from 1.77 to 1.15/100,000 women.
Trends were inconsistent in other countries, possibly due to
low numbers of deaths.
Figure 1 displays all age NPC mortality rates in 2012. The
highest rates were in Hong Kong (4.51/100,000 men and
1.15/100,000 women), followed by selected Eastern European
countries (Moldova and Romania). The lowest rates were in
Northern Europe and Latin American countries. EU rates
were 0.27/100,000 men and 0.09/100,000 women, US rates
were 0.20/100,000 men and 0.08/100,000 women and Japanese
rates were 0.16/100,000 men and 0.04/100,000 women.
Figure 2 and the corresponding Table 2 show joinpoint
analysis results for NPC mortality trends in 20 selected larger
countries worldwide between 1970 and the most recent avail-
able year. The EU showed an increasing trend for men (1.7
APC) until the 1990s, then a fall (22 APC). Women had an
inconsistent trend up to 1986, and a decline thereafter (21.9
APC).
The United States showed declines in both sexes with
AAPCs of 21.8 for men and 22.3 for women. Hong Kong
trends appreciably declined across the whole studied period,
with AAPCs of 22.9 in men and of 24.2 in women. NPC
mortality rate trends in Japanese men rose up to 1996 and
then declined signiﬁcantly; in women, the decline started in
1985.
Figure 3 and supplementary Table 1 shows NPC mortality
trend predictions for the year 2020 in the EU, the United
States and Japan. The favourable patterns in mortality are
predicted to continue, with the only exception of Japanese
men, where they appear to have reached a plateau.
Discussion
In this up to date global analysis, we found a downward
trend in NPC mortality for most countries worldwide. There
were inconsistent trends in some European and Latin American
countries, possibly attributable to random variation from low
numbers of deaths, improved diagnosis and validity of cause of
death certiﬁcation.
Tobacco smoking and alcohol drinking are associated
with KSCC,27,47 which tends to be comparatively more fre-
quent in non-endemic regions, although NKC is observed in
those areas, too.8,22,48 Aspects of diet may also inﬂuence
KSCC. A diet rich in fruit and vegetables and a Mediterra-
nean dietary pattern has been favourably related to KSCC
risk. The RR was around 0.5 for the highest versus the low-
est adherence to the pattern in a multicentric Italian
study.49,50 Occupational exposure to wood dusts, leather,
Figure 1. Age-standardized (world population) death certification rates from nasopharyngeal cancer in men and women from 42 selected
countries worldwide plus the EU as a whole in 2012, or the last available year.
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Figure 2. Joinpoint analysis for all ages nasopharyngeal cancer mortality in men (circles) and women (squares) in 19 selected countries and
the EU as a whole, 1970–2014.
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nickel and possibly formaldehyde,28,51,52 were reported as
KSCC risk factors, although quantiﬁcation, and hence, the
public health impact for these factors, remains undeﬁned.47
Still, exposure control to these occupational risk factors over
the last decades may also account for part of NPC mortality
declines. Family history of NPC and selected genetic factors,
including human leukocyte antigen locus, have been associ-
ated with NPC risk.47 In several European countries and
North America, the prevalence of tobacco smoking showed
a decreasing trend in men (but not consistently in women)
over the last few decades.53–55 Other smoking-related can-
cers, including laryngeal and lung cancer, showed decreasing
trends mainly in men.56–58 Likewise, the decline in NPC
mortality was greater for men than for women over the last
decade. The smoking pattern in the two sexes can also
explain the earlier rises in men for the EU and several Euro-
pean countries,54 with a subsequent decline, as well as the
earlier declines in the UK and the United States for both
sexes.59,60 Alcohol drinking has also been associated with
NPC risk.27,61 Alcohol drinking increased up to more recent
years in countries of central and eastern Europe, but has
been declining in Southern Europe.60 Thus, alcohol drinking
disparity in Europe might explain at least part of the declin-
ing trends in NPC mortality in selected southern European
countries.60 Changes in tobacco smoking, and alcohol drink-
ing (as well as salted ﬁsh consumption in high risk areas)
are related to NPC risk and hence incidence, although their
impact or mortality remains difﬁcult to quantify in various
countries.
The NPC mortality rate in Latin American is relatively
low. Hence, it is possible that random variation due to low
numbers of deaths and variable cancer death certiﬁcation
validity partly or largely explain some of the observed incon-
sistent trends.
EBV, in interaction with salted ﬁsh and preserved food
consumption, which are high in nitrous compounds and vol-
atile nitrosamines, induces carcinogenic development for
NKC,24 the predominant histology in endemic areas.8,22 In
several high risk areas, a noticeable decline in NPC incidence
has been reported.7,9–12,18,19,62 Our study showed a signiﬁcant
decreasing NPC mortality in Hong Kong. In other endemic
areas, declining trends were also reported, including Tai-
wan,10 Singapore,9 Southeast Asia11,12 and North Africa.18,19
In contrast, Sinui, Cangwu2 and Zhongshan3 showed a stable
NPC mortality trend, with rates over 20/100,000 among men
and over 10/100,000 among women.2,3 We used national
mortality data from the WHO database. Thus, we were
unable to provide speciﬁc trends for Southern China (except
Hong Kong) and Malaysia, two areas with high salted ﬁsh
consumption. Data for Malaysia were available for 2007 and
2008 only. NPC all ages mortality was 2.1/100,000 men and
0.6/100,000 women.
Figure 3. Age-standardized (world population) quinquennial nasopharyngeal cancer death rates in the EU as a whole, the United States
and Japan in 1972–2012, and predicted rates to 2020 with corresponding prediction intervals.
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Lifestyle and dietary habits have changed in the last
decade, particularly in selected high mortality areas, and may
account for the favorable trends observed. A study from
Hong Kong investigated the incidence trend according to his-
tology type,8 and a declining trend was observed in KSCC,
too. This supports the notion that the decreasing trend in
smoking prevalence in men might partly account for the
downward trend in NPC mortality in high risk areas as well.
Improved management has also been associated with the
decline in NPC mortality.33,63 Diagnostic imaging accuracy
improved and intensity modulated radiotherapy (IMRT) is
established as the standard NPC treatment.33 IMRT can
decrease the comorbidity of treatment and improve treatment
compliance.32 Improvements in accessibility to medical care
may well have favorably inﬂuenced mortality trends, particu-
larly in high income countries, including Hong Kong.
In conclusion, NPC mortality showed favorable trends
over the last few decades in most countries, both in high and
low incidence areas. These favourable trends are predicted to
continue in the near future in major countries worldwide.
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